RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype

Thyroid

Volumn 17, Issue 2, 2007, Pages 101-104

  Pinna, Giovanni ^a   Orgiana, Giuseppina ^a   Riola, Alessia ^a   Ghiani, Mariangela ^a   Lai, Maria Letizia ^a   Carcassi, Carlo ^a   Mariotti, Stefano ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER GENETICS; CAUCASIAN; CODON; CONTROLLED STUDY; EXON; FAMILIAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; ONCOGENE RET; PHENOTYPE; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTO ONCOGENE; RETROSPECTIVE STUDY; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; HUMANS; ITALY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; THYROID NEOPLASMS;

EID: 33847681936     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.0198     Document Type: Article

References (27)

1. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA Jr 1986 Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73:278-281.
2. Mulligan IM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
3. Carney JA 2005 Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol 29:254-274.
4. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE 2000 Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG → ATG) mutation. Surgery 128:93-98.
5. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
6. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel KF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579.
7. Cote GJ, Gagel RF 2003 Lessons learned from the management of a rare genetic cancer. N Engl J Med 349:1566-1568.
8. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 281:1587-1588.
9. Gibelin H, Bezieau S, Misso C, Bouin-Pineau MH, Marechaud R, Kraimps JL 2004 Germline RET V804M mutation associated with multiple endocrine neoplasia type 2A. Br J Surg 91:1458-1459.
10. Frohnauer MK, Decker RA 2000 Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 128:1052-1057; discussion 1057-1058.
11. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109.
12. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525.
13. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B 2001 Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86:3746-3753.
14. Orgiana G, Pinna G, Camedda A, De Falco V, Santoro M, Melillo RM, Elisei R, Romei C, Lai S, Carcassi C, Mariotti S 2004 A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. J Clin Endocrinol Metab 89:4810-4816.
15. Sanger F, Nicklen S, Coulson AR 1977 DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467.
16. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37:817-827.
17. Lombarde F, Baudin E, Chiefari E, Arturi F, Bardet S, Caillou B, Conte C, Dallapiccola B, Giuffrida D, Bidart JM, Schlumberger M, Filetti S 2002 Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 87:1674-1680.
18. Lecube A, Hernandez C, Oriola J, Galard R, Gemar E, Mesa J, Simo R 2002 V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. Surgery 131:509-514.
19. Learoyd DL, Gosnell J, Elston MS, Saurine TJ, Richardson AL, Delbridge LW, Aglen JV, Robinson BG 2005 Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) 63:636-641.
20. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K 1999 Two germline missense mutations at codons 804 and 806 of the RET protooncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90:1-5.
21. Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD 2001 Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 38:784-787.
22. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, et al. 1995 RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419.
23. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E, Colantuoni V 1998 A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat Suppl 1:5167-171.
24. Fink M, Weinhusel A, Niederle B, Haas OA 1996 Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET protooncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Int J Cancer 69:312-316.
25. Contu D, Morelli L, Zavattari P, Lampis R, Angius E, Frongia P, Murru D, Maioli M, Francalacci P, Todd JA, Cucca F 2002 Sex-related bias and exclusion mapping of the nonrecombinant portion of chromosome Y in human type 1 diabetes in the isolated founder population of Sardinia. Diabetes 51:3573-3576.
26. Francalacci P, Morelli L, Underhill PA, Lillie AS, Passarino G, Useli A, Madeddu R, Paoli G, Tofanelli S, Calo CM, Ghiani ME, Varesi L, Memmi M, Vona G, Lin AA, Oefner P, Cavalli-Sforza LL 2003 Peopling of three Mediterranean islands (Corsica, Sardinia, and Sicily) inferred by Y-chromosome biallelic variability. Am J Phys Anthropol 121:270-279.
27. Marrosu MG, Lai M, Cocco E, Loi V, Spinicci G, Pischedda MP, Massole S, Marrosu G, Contu P 2002 Genetic factors and the founder effect explain familial MS in Sardinia. Neurology 58:283-288.